PIPE-791
PIPE-791 is an orally active, blood-brain barrier-permeable selective antagonist of LPAR1. PIPE-791 inhibits LPA-induced calcium mobilization, collagen expression, histamine release, and the activation of fibroblasts, microglia and macrophages. PIPE-791 induces oligodendrocyte precursor cell differentiation, myelination and remyelination, and increases the number of microglia in the retina of normotensive rats. PIPE-791 protects mature oligodendrocytes from cytokine-induced death, reduces the levels of pulmonary fibrosis markers and alleviates neuroinflammation in preclinical models. PIPE-791 can be used in the research of glaucoma, neuroinflammatory diseases, chronic osteoarthritis pain, idiopathic pulmonary fibrosis and multiple sclerosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2901868-37-7
- Formule: C24H29F2N3O5
- Masse moléculaire:477.50
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Histamine Receptor
More
Activité biologique
|
LPA1 Receptor |
IL-1β |
CYP3A4 |
CYP2C8 |
PIPE-791 can bind strongly to the cell membrane of human LPAR1 overexpressing cells, with a Ki value of 0.752 nM and a Kd value of 0.341 nM; it can also inhibit LPA-induced calcium mobilization in human LPAR1 overexpressing cells, and its efficacy increases with pre-incubation time, with IC50 decreasing from 91.8 nM to 9.9 nM[2].
PIPE-791 (100 pM-10 μM; 3 h) acts as a selective LPAR1 antagonist in transiently transfected HEK293T cells, with an LPAR1 IC50 value of 8.0 nM[2].
PIPE-791 exhibits inhibitory activity against PDE3A with an IC50 of 9.0 μM; it also acts as a partial agonist for CNR1 with an EC50 of 15.1 μM, and shows no significant activity against most other screened targets[2].
PIPE-791 induces CYP3A4 in cryopreserved human hepatocytes with an EC50 of 25.6 μM; it directly and time-dependently inhibits CYP2C8, with IC50 values of 17.4 μM and 7.73 μM[2].
PIPE-791 inhibits OATP1B1 (IC50 = 3.5 μM), OAT3 (IC50 = 23.0 μM), OATP1B3 (IC50 = 20.7 μM) and BSEP (IC50 = 24.4 μM), and shows no obvious inhibitory activity against most other tested human transporters. Its IC50 value against LPAR1 reaches 8 nM in HEK293T cells. It potently suppresses LPA-triggered chemotaxis (IC50 = 1.5 nM) and COL1A1 expression (IC50 = 1.1 nM) in primary adult pulmonary fibroblasts. Besides, it blocks myofibroblast transformation induced by TGFβ1 or LPA[2].
PIPE-791 (0.03-3 µM; 48 h-6 days) reduces the expression of key fibrotic genes (COL1A1, COL3A1, SERPINE1, TIMP1) in 6-day cultures of precision-cut lung slices (PCLS) derived from pulmonary fibrosis donors, and decreases the levels of secreted C3M and Pro-C6 biomarkers in 48-hour cultures of fresh PCLS derived from pulmonary fibrosis donors[3].
PIPE-791 potently binds to human LPA1 receptors in recombinant membranes, with a Ki value of 0.752 nM and an IC50 value of 2.63 nM. It binds to LPA1 receptors in native human brain homogenate with a Kd value of 0.68 nM, and binds to LPA1 receptors in native mouse brain homogenate with a Kd value of 1.7 nM[4].
PIPE-791 induces the differentiation of primary rat O4+ oligodendrocyte precursor cells (OPCs) into mature oligodendrocytes in a dose-dependent manner, with an EC50 of 108 nM; it promotes functional myelination of axons by oligodendrocytes in primary rat cortical culture systems, with an EC50 of 2.6 nM[4].
PIPE-791 (300 nM; 48 h) reverses the inhibitory effect of macrophages on the differentiation of primary rat oligodendrocyte precursor cells (OPC)[4].
PIPE-791 (3 μM; 2 h pre-incubation, 3 h with LPA) inhibits lysophosphatidic acid (LPA)-induced activation of microglia and maintains their branched morphology in hippocampal slices from postnatal day 20 mice[4].
PIPE-791 (0.001 μM-3 μM; 72 h) dose-dependently protects mature rat oligodendrocytes against TNFα/IFNγ-induced cell death, with an EC50 of 125 nM[4].
PIPE-791 (0.001 nM-1 μM; 72 h, 5 days) promotes remyelination in postnatal day 17 mouse cortical slices demyelinated by lysophosphatidylcholine, with an EC50 value of 12.1 nM for Mbp transcript induction, 74 nM for the increase in MBP-positive areas, and 17.9 nM for the increase in Caspr punctate structure count[4].
PIPE-791 (0.3 nM-300 nM; 9 days) dose-dependently induces oligodendrocyte differentiation in adult cortical slices, with an EC50 of 4.2 nM for inducing Mbp transcripts, and the number of CC1+ oligodendrocytes increases significantly at 300 nM[4].
PIPE-791 (0.001 nM-1 μM; 15 h+5 h for rat cells, 6 h+4 h for human cells) inhibits lysophosphatidic acid (LPA)-induced activation of rat and human meningeal fibroblasts, with IC50 values of 31.8 nM and 4.5 nM, respectively[4].
PIPE-791 inhibits LPS-induced IL-1β secretion in primary human alveolar macrophages in vitro[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
PIPE-791 (0.03-3 mg/kg; p.o.; daily administration; for 15 consecutive days) dose-dependently improves body weight, increases survival rate, and reduces the levels of multiple fibrosis markers and pulmonary collagen in a mouse model of pulmonary fibrosis induced by oropharyngeal administration of Bleomycin (HY-108345)[3].
PIPE-791 (3 mg/kg; p.o.; once daily; for 29 consecutive days) reduces pulmonary collagen levels to those of the control group in a mouse model of subcutaneous Bleomycin-induced chronic pulmonary fibrosis[3].
PIPE-791 (0.003-3 mg/kg; p.o.; single administration or daily administration for 4 consecutive days) exhibits long-term LPAR1 receptor binding kinetics in healthy mice. Its receptor occupancy potency at 24 h after single administration is 20-fold higher than that at 3 h, and receptor occupancy can be maintained at steady state at low doses[3].
PIPE-791 (3 mg/kg; p.o.; single administration) increases mature oligodendrocytes in healthy mice by 163%[4].
PIPE-791 (0.03-3 mg/kg; p.o.; single dose/once daily; up to 4 days) achieves dose-dependent, long-lasting LPA1 receptor occupancy in mouse brains, with an ED50 of 0.17-0.19 mg/kg for a single dose and an ED50 of 0.03 mg/kg at steady state. Moreover, receptor occupancy persists for up to 7 days after a single 3 mg/kg dose[4].
PIPE-791 (3 mg/kg; p.o.; once daily; for 11 consecutive days) reduces Bleomycin-induced macrophage activation and IL-1β secretion in a mouse model of pulmonary fibrosis established by intratracheal injection of Bleomycin[3].
PIPE-791 (0.3-3 mg/kg; p.o.; single administration or daily administration for 4 days) dose-dependently inhibits LPA-induced mast cell histamine release in healthy mice, with the pharmacodynamic effect lasting for 24 hours after administration and enhanced under steady-state conditions[3].
PIPE-791 (0.3-3 mg/kg; p.o.; once daily; for 25 consecutive days) significantly reduces disease severity, improves myelination, restores visual evoked potential latency, and decreases microglial activation in MOG-EAE mouse models of multiple sclerosis[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley, Göttingen minipigs (male and female)[2]
-
Dosage:30 mg/kg/day; 100 mg/kg/day; 1000 mg/kg/day
-
Administration:p.o.; daily; 28 days
-
Result:Observed no test article-related mortality or adverse findings at any dose.
Observed no signals of hepatobiliary toxicity or neurotoxicity, even at the 1000 mg/kg/day dose.
-
Animal Model:C57BL6/N (female, 8-10 weeks old, oropharyngeal bleomycin-induced pulmonary fibrosis)[3]
-
Dosage:0.03 mg/kg; 0.3 mg/kg; 3 mg/kg
-
Administration:p.o.; daily; 15 days
-
Result:Improved body weight by 28% compared to bleomycin/vehicle controls at 0.03 mg/kg.
Improved body weight by 41% compared to bleomycin/vehicle controls at 0.3 mg/kg.
Improved body weight by 38% compared to bleomycin/vehicle controls at 3 mg/kg.
Prevented deaths in all dosed groups, compared to 3 deaths in the bleomycin/vehicle group.
Reduced BALF procollagen by 65%, TGFβ1 by 51%, and TIMP1 by 57% compared to bleomycin/vehicle controls at 3 mg/kg.
Reduced lung hydroxyproline by 41% compared to bleomycin/vehicle controls at 0.3 mg/kg.
Reduced lung hydroxyproline by 39% compared to bleomycin/vehicle controls at 3 mg/kg.
-
Animal Model:C57BL/6 (female, 9 weeks old, subcutaneous bleomycin-induced chronic pulmonary fibrosis)[3]
-
Dosage:3 mg/kg
-
Administration:p.o.; daily; 29 days
-
Result:Reduced bleomycin-induced lung tissue collagen fraction to levels comparable to vehicle/vehicle controls, with a significant reduction compared to bleomycin/vehicle controls.
Reduced bleomycin-induced lung hydroxyproline levels by 40% compared to bleomycin/vehicle controls, with levels not significantly different from vehicle/vehicle controls.
-
Animal Model:CD-1 (female, intratracheal bleomycin-induced pulmonary fibrosis)[3]
-
Dosage:3 mg/kg
-
Administration:p.o.; daily; 11 days
-
Result:Reduced bleomycin-induced macrophage size (measured by CD68 area) by 56% compared to bleomycin/vehicle controls.
Reduced bleomycin-induced IL-1β levels in BAL fluid by 69.2% compared to bleomycin/vehicle controls.
-
Animal Model:CD-1 (female)[3]
-
Dosage:0.3 mg/kg; 3 mg/kg
-
Administration:p.o.; single dose or daily; 4 days
-
Result:Significantly blocked histamine release at both 3 and 24 hours post-dose at 3 mg/kg single dose.
Significantly blocked histamine release at 24 hours but not 3 hours post-dose at 0.3 mg/kg single dose.
Significantly blocked histamine release at both 3 and 24 hours after the final dose at both 0.3 mg/kg and 3 mg/kg with 4 daily doses.
-
Animal Model:C57BL6/N (female, single-dose occupancy)
C57BL/6 (female, steady-state occupancy)[4] -
Dosage:0.03-1 mg/kg (single-dose/steady-state occupancy); 3 mg/kg (extended occupancy time course)
-
Administration:p.o.; single dose (assessed 2 h or 24 h post-dose, single-dose/extended occupancy); p.o.; once daily; 4 consecutive days (assessed 2 h after fourth dose, steady-state occupancy)
-
Result:Achieved dose-dependent LPA1 receptor occupancy with an ED50 of 0.17 mg/kg (assessed 2 h post-dose) and 0.19 mg/kg (assessed 24 h post-dose); unbound brain EC50 was 2.2 nM.
Reduced the ED50 to 0.03 mg/kg at steady state, with an unbound brain EC50 of 2.4 nM.
Sustained LPA1 occupancy for 24 h after a single 3 mg/kg dose, with occupancy slowly decreasing over 7 days, while plasma concentrations peaked at 2 h and were undetectable after 3 days.
-
Animal Model:C57BL/6 (female, 12 per treatment group, MOG35-55/CFA emulsion + pertussis toxin-induced multiple sclerosis model)[4]
-
Dosage:0.3 mg/kg; 3 mg/kg
-
Administration:p.o.; once daily; 25 consecutive days
-
Result:Significantly mitigated body weight loss relative to vehicle; cumulative body weight was significantly increased in both treatment groups (0.3 mg/kg: p=0.0126; 3 mg/kg: p=0.0003).
Delayed disease onset to Day 14 in both treatment groups; peak clinical scores reached 2.1 (0.3 mg/kg) and 1.4 (3 mg/kg) compared to 3.2 in vehicle-treated mice; cumulative disease index was significantly reduced at 3 mg/kg (p=0.0092), with a trending improvement at 0.3 mg/kg (p=0.0575).
Shortened N1 latencies to 54.6 ms (0.3 mg/kg) and 52 ms (3 mg/kg) compared to 60.9 ms in vehicle-treated mice (non-EAE control latency: 56.4 ms).
Increased myelinated axons (g-ratio <1) in spinal cord to 83.3% (0.3 mg/kg) and 84.6% (3 mg/kg) compared to 73.4% in vehicle-treated mice (non-EAE control: 90.9%); increased thinly myelinated axons (1 > g-ratio ≥0.8) in spinal cord to 32.3% (0.3 mg/kg) and 31.9% (3 mg/kg) compared to 23.6% in vehicle-treated mice (non-EAE control: 31.2%).
Increased myelinated axons (g-ratio <1) in optic nerve to 85.5% (0.3 mg/kg) and 86.1% (3 mg/kg) compared to 68.7% in vehicle-treated mice (non-EAE control: 86.4%); increased thinly myelinated axons (1 ≥ g-ratio ≥0.8) in optic nerve to 44.7% (0.3 mg/kg) and 50.6% (3 mg/kg) compared to 30.2% in vehicle-treated mice (non-EAE control: 50.7%).
Significantly reduced IBA1 staining (marker of activated microglia) in the 3 mg/kg treatment group relative to vehicle-treated mice.
Chemical Information
-
CAS No. 2901868-37-7
-
Masse moléculaire 477.50
-
Formule C24H29F2N3O5
-
SMILES
COC1=NC(OC(F)F)=C(NC(N([C@@H]2CC[C@@H](C(O)=O)CC2)C3=CC=CC=C3C(C)C)=O)C=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Kocherlakota S, et al. Pharmacological Blockade of LPAR1 Does Not Provide Neuroprotection in a Rat Model of Ocular Hypertensive Glaucoma. Translational vision science & technology. 2026 Jan 05;15(1):11. [Content Brief]
[2]. Chen A, et al. Discovery of , A Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders. Journal of medicinal chemistry. 2026 Jul 09;69(13):15888-15927. [Content Brief]
[3]. Poon M, et al. The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis. Respiratory research. 2025 Aug 31;26(1):265. [Content Brief]
[4]. Poon MM, et al. Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis. Scientific reports. 2024 May 08;14(1):10573. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PIPE-791 Related Classifications
HY-184986 Related Classifications
Powered by Bioz